

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12M 1/42, C12N 13/00		A1	(11) International Publication Number: WO 95/23211
			(43) International Publication Date: 31 August 1995 (31.08.95)
(21) International Application Number: PCT/US95/02309		(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).	
(22) International Filing Date: 24 February 1995 (24.02.95)		<p>Published <i>With international search report.</i></p>	
(30) Priority Data: 108775 25 February 1994 (25.02.94) IL			
(71) Applicant: RAMOT-UNIV. AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT LTD. [IL/IL]; Tel Aviv University, 32 Haim Levanon Street, Tel Aviv (IL).			
(71) Applicant (for MW only): SHOSHAN, Herbert, Z. [US/IL]; 544 Agur, Makabim (IL).			
(72) Inventors: KORENSTEIN, Rafi; 59 Sireni Street, Rehovot (IL). ROSEMBERG, Yosef; 16/7 Keren Hayesod Street, Ra'Anana (IL). ZAN-BAR, Israel; 7 Shkolnik Street, Rehovot (IL).			
(74) Agent: KOHN, Kenneth, I.; P.O. Box 4390, Troy, MI 48099 (US).			

(54) Title: APPARATUS AND METHOD FOR EFFICIENT INCORPORATION OF MOLECULES INTO CELLS

(57) Abstract

A method and apparatus for incorporating macromolecules into membrane vesicles, cells or tissue by electroporation is presented. The method involves the steps of: a) applying a train of low unipolar or alternating voltage pulses to the macromolecules and cells, b) increasing the concentration of the macromolecules at the surface of the cells, and c) allowing the macromolecules to penetrate into the cytosol of the cells through the destabilized cell membrane. The apparatus includes a support plate (36) having apertures for allowing electrodes (22) to pass therethrough. Support tubes (34) located within the apertures surround the electrodes (22). An electric current supplying mechanism (32) connected to the electrodes (22) supplies sufficient electrical current to a cell for facilitating the introduction of macromolecules into the cell.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

-1-

APPARATUS AND METHOD FOR EFFICIENT
INCORPORATION OF MOLECULES INTO CELLS

5

TECHNICAL FIELD

This invention relates to a system for transferring molecules into cells and, more particularly, to a pulsed low voltage system capable of macromolecular transfer.

BACKGROUND OF THE INVENTION

In order to introduce molecules into cells, the permeability barrier of the cell membrane must be overcome. Present day research has created two categories of approach for loading cells with otherwise membrane impermeable molecules.

In a first method, low molecular weight molecules are incorporated into cells based either on the employment of lipophilic molecules which are modified into hydrophilic molecules following their penetration into the cytosol by intracellular enzymes, such as esterases which act on, in example, the pH indicator 2',7'-bis(2-carboxyethyl)-5(6)-carboxyfluorescein, acetoxymethyl ester or by adenosine tri-phosphate induced formation of small pores in the membrane.

The second method relates to the incorporation of high molecular weight molecules and is based on several approaches. One approach is the use of chemicals such as detergents, polyethyleneglycol, and lipofectin. Additional approaches include liposome-cell fusion, electroporation, and cell bombardment by coated molecules.

A problem with these methods is that they are either destructive of cells or the methods are inefficient and are of restricted commercial use.

-2-

An application requiring the introduction of molecules into cells is the field of gene therapy. In this application, macromolecules, generally DNA, must be introduced into the cell. The cells must be transfected with the DNA leading to transformed viable cells.

While significant progress has been made in manipulating cellular genes, the application to gene therapy has been limited and the field of gene therapy is still not commercially developed. One major limiting factor to apply gene therapy effectively is the need to achieve a very high number of transformed cells. In most cases following transfection, transformation does not occur and neither further selection nor multiplication of cells can be achieved. Thus, the efficiency of transfection resulting in transformation is the rate limiting step for applications of gene therapy.

One successful approach in gene therapy has been to use a gene spliced into a retrovirus as a vector to introduce the gene into the target cell. However, the disadvantage of this strategy is that it involves the multiplication of target cells *in vitro*. Other limitations of this approach are the limited size of the gene that can be carried by the vector and be implanted and the procedures needed to express only the target gene without the additional expression of the viral genes. This procedure is limited to DNA and does not accommodate other molecular species that could, for example, lead to the intracellular employment of exogenous enzymes, such as restriction enzymes, for gene manipulations.

Fusing liposomes is another approach. The liposomes are loaded with the appropriate genes and are fused with the target cells.

An alternative procedure for the introduction of genes into cells is based on exposing the cells to exogenous DNA in high electric fields, the procedure being known as electroporation. Electroporation can be generally

-3-

defined as formation of hydrophilic pores through an electrical process where larger pores allow higher permeability. Electroporation utilizes short, high voltage electrical pulses to produce a transient high permeability state (reversible electrical breakdown, REB) which occurs at the beginning of the high permeability state. REB is a decrease in the electrical resistance of a tissue which is caused by brief exposure to an abnormally high transtissue potential.

United States Patent 5,019,034 to Weaver discloses the use of a high voltage, short duration electrical pulse on the tissue surface to produce electroporation of molecules into cells of the tissue.

However, these existing methods suffer from at least one of the following problems:

(1) There is a low efficiency of loading or transfection of high molecular weight molecules (i.e., macromolecules).

(2) The demonstrated loading of macromolecules appears limited to DNA. There is a lack of loading of high molecular weight proteins, enzymes of the molecular weight of 250 kD and higher, as disclosed in the literature.

(3) Many of the extensively used methods involve steps for transfection that have a high rate of cell killings.

The present invention provides an alternative method to the above, which not only enables the incorporation into cells of macromolecules without destruction of the cells, but also provides an efficient introduction of the molecules. The method can be accomplished *in vivo* or *in vitro*.

Several prior art electrodes have been used for incorporating molecules into adherent cells (cells growing attached to a surface). One such electrode was based on causing cells to adhere to a first electrode surface and then applying a second electrode on top of the cells

- 4 -

adhered to the first. A second prior art electrode was based upon the application of several sets of parallel electrodes which were positioned perpendicular to the surface to which the cells were adhered. The second electrode configuration required electrode-cell contact which created the problem that because the cells were of such small size, in order to insure that the cells were in contact with the two electrodes, the electrodes had to be built to precise tolerances which were difficult to obtain.

The present invention provides an alternative electrode to the above, which not only enables the electrode to be applied to any cell topology, by also is much easier to construct.

SUMMARY OF THE INVENTION AND ADVANTAGES

According to the present invention, there is provided a method and apparatus (20) for introducing molecules and macromolecules into a membrane vesicle, a cell or tissue by (a) applying a train of unipolar or alternating low voltage pulses to molecules/macromolecules and cells, (b) increasing the concentration of molecules/macromolecules at the surface of the cells, leading to an increased interaction of the molecules/macromolecules with the membrane of the cells while also causing electrophoretic movement of charged proteins and lipids in the cell membrane, and (c) causing the destabilization of the cell membrane whereby the molecules/macromolecules penetrate into the cytosol via an endocytic process and via diffusion through structural defects in the membrane lipid bilayer.

The present invention allows the introduction of molecules into cells and is not limited by the molecular weight of the molecules. There is a very high efficiency of incorporation of the molecules, including macromolecules, resulting in cytoplasmic concentrations that are at least an order of magnitude higher than the

-5-

extracellular concentration of the molecule and macromolecules. The present invention also has a high survival rate of the treated cells. The method utilizes similar electrical parameters for the incorporation of molecules, including macromolecules, into different cell types. This permits ease of use of the invention.

The present invention also includes an apparatus (20) which includes a support plate (36) having apertures (38) for allowing electrodes (22) to pass therethrough. Support tubes (34) located within the apertures (38) slideably surround the electrodes (22). Electric current supplying means (32) connected to the electrodes (22) supplies sufficient electrical current to a cell for facilitating the introduction of molecules or macromolecules into the cell.

BRIEF DESCRIPTION OF THE DRAWINGS

Other advantages of the present invention will be readily appreciated as the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying drawings wherein:

FIGURE 1A is a bar graph comparing incorporation of 70 kD (Dextran-FITC) and 486 kD (Dextran-FITC) intracellularly into lymphocytes (Lymphoma B cells, I29) by electroporation (horizontal cross-hatching) as compared to the method of the present invention (diagonal cross-hatching), indicating the percentage of fluorescent cells, the electroporation being carried out by expressing the suspension to ten pulses of 1600 V/cm, 200 μ sec duration of each pulse;

FIGURE 1B is a bar graph comparing incorporation of 70 kD (Dextran-FITC) and 486 kD (Dextran-FITC) intracellularly into lymphocytes (Lymphoma B cells, I29) by electroporation (horizontal cross-hatching) as compared to

-6-

the method of the present invention (diagonal cross-hatching);

5 FIGURE 2 is a bar graph showing the incorporation of 70 kD (Dextran-FITC) and 486 kD (Dextran-FITC) into membrane vesicles (thylakoids) and comparing the present invention (diagonal cross-hatching) to the method of electroporation (horizontal cross-hatching);

10 FIGURE 3A is side view of the apparatus of the present invention showing electrodes in a disengaged position;

FIGURE 3B is a side view of the apparatus of the present invention showing the electrodes in an engaged position;

15 FIGURE 4A is a schematic diagram illustrating connection of a pulse generator to the electrodes in the disengaged position;

FIGURE 4B is a schematic diagram illustrating the connection of the pulse generator to the electrodes in an engaged position;

20 FIGURE 5 is a top view of a main support plate of the present invention;

FIGURE 6 is a side view of the electrodes of the present invention;

25 FIGURE 7 is a top view of a conductive plate of the present invention connected to the pulse generator;

FIGURE 8A is a diagram illustrating an embodiment of the present invention in which a direct current is applied to the electrodes;

30 FIGURE 8B is a diagram illustrating an embodiment of the present invention in which an alternating current is applied to the electrodes through a conductive plate;

35 FIGURES 9A-D are photographs showing the intercellular incorporation of molecules of 150 kD Dextran-FITC by the present method into Lewis lung carcinoma cells adherently growing in petri dishes, wherein the cells were incubated in a low conductive medium composed of 0.3 M

- 7 -

Manitol, 1.5 mM Hepes, pH=7.4. 20 mM 150 kD Dextran-FITC was added to the medium and where (A) Control (Phase microscope), (B) Control (fluorescent microscope), (C) Exposed ten minutes to a stimulus (D.C.) of 100 V/cm, 0.9 mSec, 1000 Hz (Phase microscope), (D) Exposed ten minutes to a stimulus (D.C.) of 100 V/cm, 0.9 mSec, 1000 Hz (fluorescent microscope) and the red fluorescence is produced by propidium iodide which was added to both samples in order to determine the proportion of dead cells;

FIGURES 10A-D are photographs showing the intracellular incorporation of molecules of 2000 kD Dextran-FITC by the present method into Lewis lung carcinoma cells adherently growing in petri dishes, wherein a medium comprising BGJ + 10% FCS into which 0.194 mM of 2000 kD Dextran-FITC was added and wherein (A) Control (Phase microscope), (B) Control (fluorescent microscope), (C) Exposed forty minutes to a stimulus (D.C.) of 90 V/cm, 0.9 mSec, 1000 Hz (Phase microscope) and (D) Exposed forty minutes to a stimulus (D.C.) of 90 V/cm, 0.9 mSec, 1000 Hz (fluorescent microscope); and

FIGURES 11A-D are photographs showing the intracellular incorporation of molecules of 70 kD Dextran-FITC Lewis lung carcinoma cells adherently growing in petri dishes, wherein the train of unipolar pulses was replaced by an A.C. stimulus and the medium of the reaction was BGJ + 10% FCS to which 20 mM of 70 kD Dextran-FITC was added and wherein (A) Control (Phase microscope), (B) Control (fluorescent microscope), (C) Exposed fifty minutes to a stimulus (A.C.) of 60 V/cm, 30 kHz (Phase microscope), (D) Exposed fifty minutes to a stimulus (A.C.) of 60 V/cm, 30 kHz (fluorescent microscope).

- 8 -

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

Generally, the present invention provides a method and apparatus for the introduction of molecules, including macromolecules, into a cell. The method is accomplished by the general steps of preparing either a suspension or an adherent growth of the cells and molecules to be introduced into the cells, and applying a train of unipolar or alternating low voltage pulses to the suspension or adherent layer to increase the concentration of the molecules at the cell surface. This leads to an increased interaction of the molecules/macromolecules with the lipid bilayer of the cell membranes driven by electric and thermal forces. At the same time, the unipolar or alternating train or series of trains of voltage pulses leads to electrophoretic movement of the charged proteins in the cell membranes causing their accumulation in one half of the cell. The accumulation of molecules/macromolecules at the cell surface and the electric and thermal forces acting on the macromolecules lead to an increased interaction of the macromolecules and molecules with the cell surface leading to a destabilization of the cell membrane. Cell membrane destabilization causes penetration of molecules and macromolecules into the cytosolic compartment of the cell via endocytic process which leads to increased vesicle formation with the molecules and macromolecules, are trapped inside the vesicles and/or the macromolecules penetrate the cells via diffusion through the induced structural defects in the lipid bilayer.

More specifically, a series of pulses, such as a single train or multiple trains of unipolar low-voltage direct current (D.C.) or alternating current (A.C.) pulses, is applied to an environment containing the cells and molecules. - The term series is used to designate a single train of voltage pulses or a number of continuous repetitions of the train of voltage pulses or a number of

continuous repetitions of the train of voltage pulses. These voltage pulses can be either unipolar or bipolar. This step of the process is a critical difference from other processes, such as electroporation.

5 *In vitro*, for cells growing in suspension, the cells are suspended in a medium of low conductance in order to limit electric heating effects and/or electrolytic reactions at the electrode - medium interface. Such medium may consist of 300 mM sucrose or mannitol in the presence
10 of a small amount of a buffer (e.g. 1 to 3 mM Hepes) of a pK in the pH range of 7.0 to 8.0. In some cases, 5% glycerol can be added to the medium in order to enhance incorporation. Following the exposure to the electric field, the cells should be washed with PBS or growth medium
15 and finally replacing the medium with fresh growth medium in the presence of 5%-10% FCS (fetal calf serum) or bovine calf serum. The train or series of trains of unipolar voltage pulses is applied by the application of two electrodes to the suspension. The electrodes could be made
20 from different metal with the preference of using inert and non-polarizable electrodes (e.g., platinum or Ag/AgCl electrodes, correspondingly).

In vitro, for cells growing while attached or adhered to a surface such as a petri dish or culture flask,
25 the cells are adhered to a surface by growth in a suitable growth medium as shown in Figures 9A-D, 10A-D, and 11A-D. The growth medium is then removed and replaced with a suitable incubation medium such as BGJ media supplemented with 10% FCS. An alternating current field (60 V/cm at 30
30 kHz) is then applied to the cells. Following exposure to the field, the cells are washed with PBS or medium and finally replaced with fresh growth medium. Unlike the treatment of suspended cells, the incorporation of macromolecules can be carried out in the presence of a very
35 conductive medium. That is, macromolecules can be

-10-

incorporated into cells in the presence of a highly conductive medium.

The present invention can also be applied to enhance incorporation of molecules into adherent cells by utilizing both the method and apparatus of the present invention. For use with adherent cells, there is no need to change the growth medium of the cells to a low conductivity medium. That is, the same medium used for cell growth can be utilized for reaction incorporating the macromolecule. The present invention can also be utilized *in vivo* by application of the molecules to be introduced at the site or area containing the cells which are the target of the introduction. Sites such as skin and internal tissues can be targets either invasively or non-invasively.

The apparatus of the present invention, generally shown at 20 in Figure 3, is a new electrode type comprising a series of small needles 22 which are applied perpendicularly to a base 26 (plan) of a petri dish 24 containing an adherent cell layer (not shown). A lower end 28 of each needle 22, touches the base 26 of the dish 24 penetrating the cell monolayer while an upper end 30 of the needle 22 is connected to a pulse generator 32. The needles 22 are placed inside parallel tubes 34 and are held in arrangement by a support plate 36. The needles 22 can move freely within the tubes 34 so as to accommodate any cellular topology. That is, the needle electrodes 22 can move freely in the perpendicular direction to the plane of the cell or tissue layer. If the support plate 36 is thick enough, holes 38, as shown in Figure 5, in the plate 36 can replace the tubes 34.

The needle electrodes 22 of the present invention can be constructed of any suitable conductive material such as stainless steel, platinum, and other metals or alloys of metals. The needle electrode 22 can also be covered with materials such as plastic in order to reduce the conductivity of the electrode or to change the direction of

-11-

the field which is generated. Additionally, the needle electrodes 22 can be easily changed and discarded allowing for new needle electrodes 22 to be inserted thereby making the apparatus suitable for uses requiring sterility and patient contact.

The support plate 36 can be constructed of any suitable material, such as a plastic material.

Connection to the pulse generator (P.G.) 32 can be made in two different ways. The first alternative, as shown in Figures 4A-B, 6, and 8A, can be where the needles 22 are connected directly to the P.G. 32 by a very thin and properly insulated wires 40 in such a manner as to not to limit the free movement of the needles 22 inside the tube 34 or channel 38 in the main support plate 36. The insulation on the wire 40 avoids possible short circuiting of the needles 22.

Referring to Figures 3A and 8B, a second alternative is shown wherein the P.G. 32 can be connected to a conductive plate 42 which is divided into single or conductive arrays 46 filled with a conductive gel (not shown). Contact of a head 44 of the needle 22 with the conductive gel connects the needles 22 with the P.G. 32. The conductive gel can comprise any suitable conductive material such as a mixture of 1M KCl with 2% agarose.

As shown in Figure 6, the conductive array 46 of the conductive plate 42 includes a plate 48 which apertures 52 which contain the conductive gel which acts to connect leads or wires 50 which connect the conductive plate 42 to the power source P.G. 32. The apertures 52 placed in the conductive plate 42 also allow for selection or changes in the location of the electrodes 22 in order to obtain a desired electric field. In other words, the arrangement of the apertures 52 in the conductive plate 42 allows the user to configure the location of the electrodes 22 in order to either achieve a particular electric field among the cells or to configure the electrodes 22 such that the electrode

-12-

22 arrangement accommodates a particular space such as the circular conformation of a typical Petri dish 24. Additionally, the apparatus (20) does not require electrode contact with the cells in order to facilitate the incorporation molecules into the cell. The apparatus (20) creates electric field which facilitate the uptake of molecules without electrode-cell contact.

In operation, the electrode apparatus 20 can function in the following way: when the plate is pushed down towards the petri dish from a disengaged position (Figure 3A) where the electrodes 22 are elevated above the surface of the cell layer toward an engaged position (Figure 3B) where the electrodes 22 contact the cell layer and the needles electrodes 22 touch the bottom of the dish 26. Since the needle electrodes 22 are free to move inside the tubes 34, the head 44 of the needle electrode 22 moves upward with relation to the main support plate 36. Thus, when the heads 44 of the needle electrodes 22 move upward, it insures that the lower ends 28 of the needle electrodes 22 come into contact with the bottom 26 of the petri dish 24.

In the embodiment in which the P.G. 32 is connected through the conductive plate 42, the upper ends 30 of the needle electrodes 22 come into contact with the conductive gel as they move upward since the conductive plate 42 is closely positioned and parallel to the main support plate 36.

As illustrated in Figures 8A-B, the apparatus 20 of the present invention can be constructed so as to function with either a direct current (D.C.) source (Figure 8A) or as with an alternating current (A.C.) source (Figure 8B).

The effect of the present invention can be further effectuated by crosslinking the compounds to hydrophilic compounds (as carriers), such as bovine serum albumin. That is, the molecules can be found to be

-13-

5 attached (covalently and noncovalently) to hydrophilic-
charged carriers which potentiate the movement of the
molecules as the pulses are applied, whereby increasing the
efficiency of the system. The cellular effect involving
the hydrophilic outer surface of the membrane combined with
the effect of the train or series of trains of voltage
pulses enable the concentration of the molecules and
macromolecules at the cell surface. When the concentrated
molecules at the cell surface collide with the cell
10 membrane, the molecules aggregate at and into the
hydrophilic portion of the membrane. Intracellular
pinocytes are formed leading to increasing vesicle
formation intracellularly. Thus, the molecules have
achieved intracellular access. However, unlike other
15 methods, the concentrating effect of the present invention
results in an efficient concentrated introduction of the
molecules into the cells. The vesicles formed contain a
high concentration of the molecules, thereby creating an
effectively efficient introduction of the molecules into
20 the cell.

Alternatively, the same endpoint, loading or
transfection, can be achieved by inducing the movement of
cells towards non-charged molecules or macromolecules.

25 Molecules capable of incorporation by the present
invention can be defined over a wide range. That is, the
present invention enables an efficient introduction of
molecules and macromolecules into living cells *in vitro* and
in vivo. These molecules are within an extremely wide
range of molecular weight. The molecules can range from
30 the size of ions and small molecules up to proteins,
antibodies, and large enzymes. Moreover, transfection with
different DNA vectors may be possible by use of the present
inventive method either by itself or in combination with
other methods of transfection thereby enhancing the
35 effectiveness of those methods. Other existing methods of
incorporation include incorporation of macromolecules based

-14-

on the use of chemical compounds e.g., DNA transfections based on the use of calcium phosphate precipitation.

As stated above, the present invention is based on electric field induced relative movement of charged molecules, charged macromolecules, or charged liposomes toward cells (or the converse) using appropriate electric field parameters which yield an accumulation of the charged entities near the cell membrane. Unlike prior art methods, the present invention does not use either high voltages, such as electroporation, or frequencies which create summation of voltage pulses in a way where the effective pulse is a summation of several pulses, resulting in equilibrating molecules between the extracellular and intracellular compartments. This method differs from electroporation (or the equivalent terms) by the following features:

1. The electric parameters used by the present invention to efficiently incorporate molecules/macromolecules into cells induce a transmembrane potential difference across the cell membrane which is much lower than the known threshold of transmembrane potential difference which causes electroporation to take place.

2. Electroporation and consequent uptake, under specific electric field parameters, were shown to be proportional to the volume of the biological object (e.g. cell, bacteria etc) which is exposed to the electric field. Under the experimental conditions of the present invention, the uptake by the method of the present invention is independent on the volume of the exposed biological object and may be proportional to the surface area of the object.

3. Uptake is not limited by the electrochemical potential difference across the membrane concentration. Under conditions of electroporation, at most the same concentration of molecules/macromolecules in the cytosol and in the external medium can be achieved. Under experimental conditions, applicants have demonstrated up to

-15-

two orders of magnitude increase of molecules/
macromolecules concentration in the cytosol as compared
with the concentration in the external medium.

More specifically, in order to achieve an
increased incorporation of the molecules into cells, the
cell suspension or the cells adhered to a surface in the
presence of the molecular entity to be incorporated are
exposed to an electric field produced by several trains of
electrical pulses. The amplitude of the voltage in each
train or series of trains of pulses is in the amplitude
range of 1 V/cm to 250 V/cm. The frequency range of the
pulses is from 1 Hz to 50 MHz possessing pulse widths of 20
ns to 20 ms in the case of unipolar pulses (D.C.) and 10-
100 kHz for bipolar (A.C.) pulses. The exact field
characteristics to be applied depends upon the charge and
the molecular weight of the specific molecules to be
incorporated.

The present invention has possible applications
in various fields. The present invention can be used to
load drugs into cells for slow drug release. In this
application, the drugs are the molecules being transferred
into the cells via the present invention. Other molecules,
such as dyes and tracers, can be loaded into cells for
imaging-based diagnosis. *In-situ* enzymology (loading
agents for diagnostics) can be accomplished. Loading of
antibodies for therapy or diagnostics can be carried out.

The present invention can be used for
incorporating drugs into specific cell or tissue types, for
example loading of drugs into tumor tissue for cancer
therapy. Likewise, enzymes can be loaded into cells for
specific purposes.

Another area for use of the present invention, as
discussed above, is in the field of genetic engineering and
gene therapy. The present invention can be used as a means
of transfection, as well as tissue gene therapy.

-16-

The above list of utilities is only a sampling of the possibilities for which the present invention can be used. The list is intended to be exemplary and not exhaustive of the uses of the present invention.

5 The following examples illustrate the application of the present invention:

Materials and Methods

10 In the following examples, the following general conditions were used; any modifications are included with the specific example. Cells were generally treated at a concentration of $1-4 \times 10^6/\text{ml}$. Prior to exposure to the electric field, the cells were washed twice with reaction medium. The exposure to the electric field was carried out in reaction medium at a temperature range of 2°C to 38°C .
15 The molecule to be incorporated was also in the reaction medium at a concentration as detailed in the following examples, but generally within the range of $0.5 \mu\text{M}$ to 0.1 mM . The molecule is in the medium during exposure to the external electric field. Sometimes it is placed in ice for
20 a short period after exposure to the external electric field. Following exposure, the cells were washed twice with the reaction medium. For long-term experiments, the cells were washed twice, after exposure, with culture medium containing 10% fetal calf serum and then cultured.

25 Cell viability following exposure was determined by trypan blue exclusion or propidium iodide uptake. In general, 40 minutes following exposure there was no viability difference between treated and untreated cells based on trypan blue exclusion. Proliferation was
30 determined by ^3H -thymidine incorporation and also by cell counting. Following exposure, the lymphocytes were screened for their ability to continue producing antibodies after being exposed to lipopolysaccharide (LPS). Uptake of molecules was measured by fluorescence microscopy or by a
35 biochemical assay.

-17-

In general, the electric fields to which the cells were exposed consisted of several trains of pulses. The amplitude of the voltage in each train of pulse is in the amplitude range of 10V/cm to 250V/cm. The frequency range of the pulses is from 1 Hz to 50 MHz possessing pulse widths of 20 ns to 20 ms. The exact field characteristics to be applied depends upon the charge and the molecular weight of the specific molecules to be incorporated and is provided in the examples. The choice of the applied electric field also depends upon the medium composition and viscosity.

Example 1

Five cellular systems were successfully treated by the method of the present invention to introduce 70 kD dextran into the cells with the experimental parameters summarized in Table 1. Percent uptake of the molecule was measured by the number of fluorescent cells with the results presented in Table 2. In general, 80-100% of the cells showed uptake, i.e. fluorescence, of the dextran. The medium of the reaction is composed of 0.3 M mannitol or sucrose and 1 mM buffer Hepes -NaOH or Tris-HCl, PH 7.0-8.0. The conductivity of the final medium is very low (<200 μ MHO), so that the cells are washed three times in this medium before the exposure to the electric fields. After the exposure, the cells can be exposed to a 5%-10% glycerol in the medium of the washes. After the reaction, the cells are washed three times with the medium used for the culture of this specific line of cells. (RPMI +10% fetal calf serum, DMEM +10 fetal calf serum, PBS, etc.)

-18-

TABLE 1

(uptake of 70 kD Dextran)

5 Red Blood Cells (RBC):Concentration: 20 μ M

Medium: 0.3 M mannitol 1 mM Hepes-NaOH

Amplitude of electric field: 100 V/cm

10 Duration of electric field: 90 μ sec at 1,000 HzFrequency: 120-1,000 Hz - (pulse width 90 μ sec)

Time of single exposure: 21 seconds

Total number of exposures: 1

15 B-Lymphocytes (I₂₉):Concentration: 20 μ M

Medium: 0.3M sucrose, 1.2 mM tris-HCl, pH 8.0

Amplitude of electric field: 150 and 200 V/cm

20 Duration of electric field: 0.9 milliseconds

Frequency: 120 Hz

Time of a single exposure: 21 seconds

Total number of exposures: 6

Time between exposures: 40 seconds

25

Cos 5-7:Concentration: 20 μ M

Medium: 0.3M mannitol, 1 mM Tris pH 8.0

30 Amplitude of electric field: 100 V/cm

Duration of electric field: 0.9 milliseconds

Frequency: 200 Hz

Time of exposure: 21 seconds

Number of exposures: 5

35 Time between exposures: 40 seconds

Swollen thylakoid vesicles:Concentration: 20 μ M

40 Medium: 1.2 mM tris-HCl, pH 8.0

Amplitude of electric field: 100 V/cm

Duration of electric field: 0.9 milliseconds

Frequency: 200 Hz

Time of exposure: 21 seconds

45 Number of exposures: 5

Time between exposures: 40 seconds

-19-

Red Blood Cell Ghosts (Low pH Ghosts):Concentration: 1 μ M

Medium: 0.3 M sucrose, 1.2 mM tris-HCl, pH 8.0

5 Amplitude of electric field: 150 V/cm

Duration of electric field: 0.9 milliseconds

Frequency: 120 Hz

Time of exposure: 21 seconds

Number of exposures: 6

10 Time between exposures: 40 seconds

-20-

TABLE 2

	<u>Cellular System</u>	<u>% Cellular Uptake</u>
	RBC	80%-100%
5	Lymphocytes I ₂₉	80%
	Cos 5-7	80%-100%
	Swollen thylakoids vesicles	80%
	RBC (Ghosts)	80%-100%

10 As shown in Table 2, the cells all were
fluorescent indicating the uptake of the 70kD-FITC dextran.
The results for the swollen thylakoid vesicles refers to
the population of vesicles which can be easily visualized
under the microscope (1-10 μ M). This is due to the fact
15 that the vesicles are extremely heterogeneous in size, and
it is difficult to determine an exact number. Also, the
thylakoid membrane has an intrinsic red fluorescence, while
the dextran was an FITC conjugate. Therefore, to
distinguish uptake from binding, the vesicles were
20 osmotically shrunk so that the value/area ratio changed.

Example 2

25 Eight cellular systems were treated by the method
of the present invention to introduce 486 kD dextran into
cells under the conditions detailed in Table 3. The
treatment was successful in 80-100% of the cell population
(Table 4).

-21-

TABLE 3

(uptake of 486 kD Dextran)

5

Red Blood Cells (RBC):Concentration: 0.5 μ M

Medium: 0.3 M mannitol, 1 mM Hepes pH 7.0

10

Amplitude of electric field: 150 V/cm

Duration of a single electric field pulse: 90 μ seconds

Frequency: 1,000 Hz

Total time of exposure: 10 minutes

Number of exposures: 1

15

Lewis Lung (LL) Carcinoma:

20

Concentration: 0.5 μ M

Medium: 1mM tris-HCl, pH 8.0

Amplitude of electric field: 100 V/cm

Duration of electric field: 0.9 milliseconds

Frequency: 200 Hz

25

Time of exposure: 21 seconds

Number of exposures: 5

Time between exposures: 40 seconds

30

B-Lymphocytes (I₂₉):Concentration: 0.5 μ M

Medium: 0.3M sucrose, 1.2 mM tris-HCl, pH 8.0

Amplitude of electric field: 150 and 200 V/cm

35

Duration of electric field: 0.9 milliseconds

Frequency: 120 Hz

Time of exposure: 21 seconds

Number of exposures: 6

Time between exposures: 40 seconds

40

Cos 5-7:Concentration: 20 μ MMedium: 0.3 M mannitol, 1 mM Tris pH 8.0,
1 mM Hepes pH 7.4

45

Amplitude of electric field: 100 V/cm

Duration of electric field: 90 μ seconds

Frequency: 1000 Hz

Time of exposure: 15 minutes

50

Number of exposures: 1

-22-

Swollen thylakoid vesicles:

Concentration: 0.5 μ M
Medium: 1.2 mM tris-HCl, pH 8.0
5 Amplitude of electric field: 100 V/cm
Duration of electric field: 0.9 milliseconds
Frequency: 100 Hz
Time of exposure: 21 seconds
Number of exposures: 5
10 Time between exposures: 40 seconds

Red Blood Cell Ghosts (Low pH Ghosts):

15 Concentration: 20 μ M
Medium: 0.3 M sucrose, 1.2 mM tris-HCl, pH 8.0
Amplitude of electric field: 150 V/cm
Duration of electric field: 0.9 milliseconds
Frequency: 120 Hz
20 Time of exposure: 21 seconds
Number of exposures: 6
Time between exposures: 40 seconds

-23-

TABLE 4

	<u>Cellular System</u>	<u>% Cellular Uptake</u>
5	RBC	80%-100%
	Lewis Lung Carcinoma	80%
	Lymphocytes I ₂₉	80%-100%
	Cos 5-7	80%-100%
	Swollen thylakoids vesicles	80%
10	RBC (Ghosts)	80%-100%

These results can be compared to the results of utilizing electroporation to introduce 70kD dextran into Lymphoma B cell, I₂₉ as shown in Figure 1. Utilizing the lymphoma cells, electroporation resulted in approximately 80% dead cells and less than 5% showing any uptake of the 70 kD dextran. The method of the present invention resulted in less than 10% dead cells and greater than 90% uptake of 70 kD dextran. Similarly, utilizing membrane vesicles, as shown in Figure 2, electroporation resulted in approximately 5% of the cells showing any uptake of 70 kD dextran. The method of the present invention resulted in greater than 90% uptake of 70 kD dextran.

Example 3

B-Lymphocytes I₂₉ were successfully treated by the method of the present invention to introduce IgG-FITC into 85% of the cell population. The following parameters were used:

Concentration: 1 mg/ml
 Medium: 1.0 mM tris-HCl, pH 8.0
 Amplitude of electric field: 200 V/cm
 Duration of electric field: 0.9 milliseconds
 Frequency: 200 Hz
 Time of exposure: 21 seconds
 Number of exposures: 10
 Time between exposures: 40 seconds

-24-

Example 4

Utilizing the experimental parameters of Example 3, a specific antibody directed against tyrosine kinase and a non-specific antibody as a control were incorporated into the lymphoblasts. DNA synthesis (^3H -thymidine uptake) was measured at 48 hour post-incorporation. The synthesis of DNA was 2639 cpm as compared to the controls indicating 2411 cpm.

The loading of lymphocytes with an antibody against tyrosine phosphate (as compared to an unspecific antibody) resulted in a partial inhibition of antibody secretion from these cells. These results show a highly efficient introduction of antibodies into cells and a specific effect on the cellular machinery resulting from such an introduction. Tyrosine phosphate was chosen in order to check the involvement of tyrosine kinase with regard to the process of antibody production.

Example 5

β -Galactosidase (540 kD) was introduced into Cos5-7 cells. The amount of enzyme incorporated into the cells was obtained a calorimetric assay using o-nitrophenyl- β -d-galactopyranoside as a substrate. The activity was calculated by subtracting the background activity (control sample) and dividing by the number of cells. The β -galactosidase was successfully inserted into the cells. The parameters used for incorporation were as follows:

Concentration: 5 $\mu\text{g/ml}$
Medium: 1 mM tris-HCl, pH 8.0, 6% glycerol
Amplitude of electric field: 100 V/cm
Duration of electric field: 90 μ seconds
Frequency: 1000 Hz
Time of exposure: 21 seconds
Number of exposures: 5
Time between exposures: 40 seconds

Since the concentration of the β -galactosidase was 5 $\mu\text{g/ml}$, the number of molecules of β -galactosidase per

-25-

ml was 5.58×10^{12} given that the volume of the cells was 2.7×10^{-10} . Therefore, the number of molecules recovered was 7.2×10^4 . Theoretically, the number of molecules that could have been taken up if there was complete chemical equilibrium should have been no more than 1,496/cell. The number of molecules found per cell was 40 times larger than the theoretical calculation.

Example 6

The above examples demonstrate that the problems associated with electroporation have been overcome by the present invention. It is a very efficient method (uptake by 80-100% of the cell population) for loading molecules having molecular weights over an extended region of 1-10⁴ kD (Tables 1-3) including enzymes (e.g. β -galactosidase of 540kD), antibodies (e.g. IgG of \approx 160 kD) or plasmids (e.g. of 11.5 kD size). Moreover, a recovery of 80-90% viability of the cell population was obtained following the procedure of loading or transfection.

Example 7

Incorporation of macromolecules by exposure to alternating current (AC) stimulus. The experiments were performed with the needle electrode system of the present invention. 3LL cells were adhered to petri dishes in the presence of growth medium. The medium was removed and replaced with incubation medium. The incubation medium consisted of growth medium (BGJ) supplemented with 10% FCS. To this medium was added Dextran-FITC molecules (70 kD) at a final concentration of 20 μ M. A stimulating voltage having amplitude (peak to peak) 60 V/cm at a frequency of 30 kHz was applied for fifty minutes. Upon termination of the stimulus, the medium was removed. The petri dishes were washed six times with the same medium but without the Dextran-FITC 70 kD. The samples were then examined with a

-26-

fluorescent microscope and photographed with 400 ASA film (Kodak) as shown in Figures 11A-D.

Example 8

5 Incorporation of Dextran-FITC (2000 kD) by
unipolar voltage pulses. The experiment was performed with
the needle electrode system of the present invention. 3LL
cells formed a monolayer in petri dishes. The medium was
removed and replaced by the incubation medium consisting of
10 BGJ medium supplemented with 10% FCS. Then 2000 kD
Dextran-FITC was added to a final concentration of 0.19 μ M.
The stimulating pulsed amplitude was 90 V/cm, the duration
of the pulse was 0.9 mSec and the frequency was 1000 Hz.
The stimulus was applied for forty minutes (one train of
15 pulses). Finally, the stimulus was stopped and the medium
was removed. The petri dishes were washed six times with
the same medium but without Dextran-FITC 70 kD. The
samples were examined with a fluorescent microscope and
photographed with 400 Asa film (Kodak) as shown in Figures
20 10A-D.

The invention has been described in an illustrative manner, and it is to be understood that the terminology which has been used is intended to be in the nature of words of description rather than of limitation.

25 Obviously, many modifications and variations of
the present invention are possible in light of the above
teachings. It is, therefore, to be understood that within
the scope of the appended claims wherein reference numerals
are merely for convenience and are not to be in any way
30 limiting, the invention may be practiced otherwise than as
specifically described.

-27-

REFERENCES

Tatham and Lindau, (1990) J. Gen. Physiol.
95(3):459-76.

-28-

CLAIMS

1. A method for introducing molecules and macromolecules into a membrane vesicle cell or tissue by
5 (a) applying a train of unipolar or alternating voltage pulses to molecules/macromolecules and cells;

(b) increasing the concentration of molecules/macromolecules at the surface of the cells, leading to an increased interaction of the
10 molecules/macromolecules with the membrane of the cells while also causing electrophoretic movement of charged proteins and lipids in the cell membrane; and

(c) causing the destabilization of the cell membrane whereby the molecules/macromolecules penetrate
15 into the cytosol via an endocytic process and via diffusion through structural defects in a lipid bilayer of the membrane.

2. The method for introducing molecules and
20 macromolecules into a cell or a tissue of claim 1 wherein said applying step is further defined as applying the train of pulses having an amplitude of voltage in the range of 10V/cm to 250V/cm at a frequency range of 1 Hz to 50 MHz, and at a pulse width of 20 ns to 20 ms.

25 3. A method of claim 1 further including the steps of preparing a suspension of the cells and molecules/macromolecules to be introduced therein, and applying the train of voltage pulses to the suspension.

30 4. A method of claim 1 further including the steps of preparing an adherent growth of the cells and molecules/macromolecules to be introduced therein, and applying the train of voltage pulses to the adherent
35 cells.

-29-

5. A method of claim 1 further including the steps of introducing the molecules to an area of a population of the cells *in vivo* and applying the train of voltage pulses to the area.

5

6. An electrode system (20) for use in introducing molecules and macromolecules into a membrane vesicle cell or tissue, said electrode system (20) comprising:

10 at least one electrode (22);
 support plate means (36) having apertures (38)
extending therethrough for supporting said electrodes
(22) through said plate means (36); and
 electric current supplying means (32)
15 operatively connected to said electrodes (22) for
supplying sufficient electrical current to a cell to
facilitate the introduction of molecules or
macromolecules into the cell.

20 7. An electrode system as set forth in claim 6
further comprising support tubes (34) located within said
apertures (38), said support tubes (34) slideably
surrounding said electrodes (22).

25 8. An electrode system (20) as set forth in
claim 6, wherein said electric current supplying means
(32) comprises a electric generator.

30 9. An electrode system (20) as set forth in
claim 8, wherein said electric generator is a pulse
generator.

35 10. An electrode system (20) as set forth in
claim 6, wherein said electric current supplying means
(32) comprises a direct current source.

-30-

11. An electrode system (20) as set forth in claim 6, wherein said electric current supplying means (32) comprises an alternating current source.

5 12. An electrode system (20) as set forth in claim 6, wherein said electric current supplying means (32) further includes a conductive plate (42), said
conductive plate (42) conducting electric current through
said electrodes (22) when said electrodes (22) contact
10 said conductive plate (42).

13. An electrode system (20) as set forth in claim 12, wherein said conductive plate (42) is filled with a conductive gel material.

1 / 10




Fig-1A




Fig-1B

SUBSTITUTE SHEET (RULE 26)

2 / 1 0




Fig-2




Fig-3A




Fig-3B

SUBSTITUTE SHEET (RULE 26)




Fig-7




Fig-8A




Fig-8B

SUBSTITUTE SHEET (RULE 26)




Fig-9A




Fig-9B

SUBSTITUTE SHEET (RULE 26)




Fig-9C




Fig-9D

SUBSTITUTE SHEET (RULE 26)




Fig-10A




Fig-10B

SUBSTITUTE SHEET (RULE 26)




Fig-10C




Fig-10D

SUBSTITUTE SHEET (RULE 26)




Fig-11A




Fig-11B

SUBSTITUTE SHEET (RULE 26)




Fig-11C



Fig-11D

SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/02309

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12M 1/42; C12N 13/00

US CL : 435/173.6, 173.4, 173.3, 287; 204/180.1, 299R

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/173.6, 173.4, 173.3, 287; 204/180.1, 229R

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
Electroporation Digest

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, CA, BIOSIS, EMBASE

Search Terms: electropor7, protein#, enzyme#, antibod###, uptak###, transport###, cell

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	BIOPHYS. J., Vol. 66, No. 5, issued May 1994, M.R. Prausnitz et al., "Quantitative Study of Molecular Transport Due to Electroporation: Uptake of Bovine Serum Albumin by Erythrocyte Ghosts", pages 1522-1530, see entire document.	1-5
X	BIOPHYS. J., Vol. 60, No. 2., issued August 1991, T.Y. Tsong, "Electroporation of Cell Membranes", pages 297-306, see especially page 301.	1-5
X	US, A, 4,822,470 (CHANG) 18 April 1989, see entire document.	1-5
Y		6-13



Further documents are listed in the continuation of Box C.



See patent family annex.

•	Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A	document defining the general state of the art which is not considered to be of particular relevance		
E	earlier document published on or after the international filing date	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
O	document referring to an oral disclosure, use, exhibition or other means		
P	document published prior to the international filing date but later than the priority date claimed	*&*	document member of the same patent family

Date of the actual completion of the international search

31 MAY 1995

Date of mailing of the international search report

08 / 06 / 95

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JON P. WEBER, PH.D.

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/02309

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EXPER. CELL RES., Vol. 197, No. 2, issued 1991, D. Kim et al., "Electroporation of Extraneous Proteins into CHO Cells: Increased Efficacy by Utilizing Centrifugal Force and Microsecond Electrical Pulses", pages 207-212.	1-5
A	EXPERIENTIA, Vol. 43, No. 6, issued 1987, M.R. Michel et al., "Uptake of Macromolecules into Electroporated Cells Under Optimized Conditions for Protein Synthesis", page 676.	1-5
A	CHEM. ABSTR., Vol. 111, issued 1989, Y. Matsuda et al. "Direct Introduction of Fluorescein Isothiocyanate-Conjugate Albumin into Intact Macroconidia of Fusarium oxysporum f. sp. lycopersici by Electroporation", page 325, Abstr. No. 20359, J. PHYTOPATHOL., Vol. 125, No. 1, issued 1989, pages 89-96, see entire abstract.	1-5
A	ANAL. BIOCHEM., Vol. 194, No. 1, issued 1991, L. Graziadei et al., "Introduction of Unlabeled Proteins into Living Cells by Electroporation and Isolation of Viable Protein-Loaded Cells Using Dextran-Fluorescein Isothiocyanate as a Marker for Protein Uptake", pages 198-203.	1-5
A	BIOCHEM. CELL. BIOL., Vol. 68, No. 4, issued 1990, H. Lambert et al., "Electroporation-Mediated Uptake of Proteins into Mammalian Cells", pages 729-734.	1-5
A	IEEE ENGINEER. IN MED. AND BIOL., issued December 1986, G.A. Hofmann et al., "Electronic Genetic-Physical and Biophysical Aspects of Cellular Electromanipulation", pages 6-23.	1-5
A,P	J. IMMUNOL. METH., Vol. 170, No. 2, issued 15 April 1994, J. Lukas et al., "Efficient Transfer of Antibodies into Mammalian Cells by Electroporation", pages 255-259.	1-5
X	US, A, 5,128,257 (BAER) 07 July 1992, see entire document.	6-13
Y		1-5
A	J. CELL. BIOCHEM., Vol. 51, No. 4, issued 1993, J.C. Weaver, "Electroporation: A General Phenomenon for Manipulating Cells and Tissues", pages 426-435.	1-5
X	PLANT CELL, Vol. 2, issued July 1990, R.A. Dekeyser et al., "Transient Gene Expression in Intact and Organized Rice Tissues", pages 591-602, see especially figure 2c and page 593.	1-5

Form PCT/ISA/210 (continuation of second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/02309

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BIOPHYS. J., Vol. 58, No. 4, issued October 1990, T.-D. Xie et al., "Study of Mechanisms of Electric Field-Induced DNA Transfection II, Transfection by Low-Amplitude, Low-Frequency Alternating Electric Fields", pages 897-903, see entire document.	1-5
X	BIOPHYS. J., Vol. 58, No. 5, issued November 1990, M.-P. Rols et al., "Electropermeabilization of Mammalian Cells, Quantitative Analysis of the Phenomenon", pages 1089-1098, see entire document.	1-5
X	BIOPHYS. J., Vol. 56, issued October 1989, D.C. Chang, "Cell Poration and Cell Fusion Using an Oscillating Electric Field", pages 641-652, see entire document.	1-5

THIS PAGE BLANK (USPTO)